Indian firm Ipca Laboratories Ltd., whose formulations manufacturing sites in Silvassa and the Special Economic Zone in Indore and an active pharmaceutical ingredients (APIs) unit in Ratlam had been placed under import alert by the US Food and Drug Administration, has received a temporary breather from the agency for hydroxychloroquine sulphate and chloroquine phosphate, the antimalarials being evaluated as potential treatments for coronavirus. (Also see "Ipca On Tailspin After Three-Plant FDA Ban" - Scrip, 16 June, 2017.)
FDA ‘Exception’ For Ipca’s Chloroquine/HCQ Amid Supply Plans From Others
Import alert hit-Ipca gets a temporary reprieve from US FDA for supplies of hydroxychloroquine sulphate and chloroquine phosphate, the antimalarials in the spotlight as potential treatments for COVID-19. But with many firms committing to supplies/donations, analysts appear to be tempering enthusiasm for large windfall gains for the Indian firm.
